Sharekhan puts buy on Lupin
Sharekhan has come out with a ‘buy’ on Lupin on account of its differentiated business model with global dominance in certain products, focus on niche, less-commoditised products and geographically diversified presence in newer markets such as Japan and the US branded segment.
Cmp: Rs 598
Target price: Rs 840
“These factors will drive sustained growth and call for premium valuations,” says the report. It adds that USFDA concerns are overdone as Lupin has already addressed USFDA’s queries on these inspectional observations and is hopeful of receiving a clearance soon. “Lupin’s issues with USFDA are not as serious as those of Caraco Pharmaceuticals/Sun Pharmaceuticals and Ranbaxy Laboratories, as Lupin continues to sell all its products in the US as well as receive product approvals from all its USFDA-approved facilities.
Hence, we reiterate our buy recommendation on the stock with a price target of Rs 840,” the report said. The broking house believes that concerns on the USFDA front are more than priced into the current stock price.
Cmp: Rs 598
Target price: Rs 840
Tags: calls, daytrading, free calls, intraday, tips
Similar Posts:
Latest Query
- by Sam
Market Stats
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis
